Testing effectiveness (Phase 2)UnknownNCT04612673
What this trial is testing
A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
Who this might be right for
Non-small Cell Lung Cancer
China Medical University, China 33